Nandrolone deconate

Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma.  If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease.  Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids.  Edema may occur occasionally with or without congestive heart failure.  Concomitant administration of adrenal steroids or ACTH may add to the edema.  In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth.  This adverse effect may result in compromised adult stature.  The younger the child the greater the risk of compromising final mature height.   The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.  This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.

Due to its chemical structure nandrolone is weakly exposed to aromatase (only 20% of the aromatizing activity of testosterone).  However, not estrogenic effects are its main concern:  nandrolone has a potent progestogenic activity (20% of progesterone).  While binding to progestogenic pituitary receptors nandrolone causes increased production of prolactin, which in effect is very similar to estrogen: its effect presents in reducing testosterone production, increasing fat mass and in gynecomastia. To prevent these side effects prolactin inhibitors (cabergoline) shall always be at hand when on nandrolones cycle.

Nandrolone deconate

nandrolone deconate

Media:

nandrolone deconatenandrolone deconatenandrolone deconatenandrolone deconatenandrolone deconate